Allergan Announces FDA Has Extended The Ulipristal Acetate NDA Review Period To August 2018

DUBLIN, Feb. 28, 2018 /PRNewswire/ -- Allergan plc, (NYSE: AGN) a leading global pharmaceutical company, today announced that it was notified by the U.S. Food and Drug Administration (FDA) that the review of the New Drug Application (NDA) for...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news